A PRX302 (protein) injection directly into the prostate to treat prostate cancer that has not spread beyond the prostate
- Conditions
- Prostate cancerTherapeutic area: Diseases [C] - Cancer [C04]
- Registration Number
- EUCTR2014-003386-22-GB
- Lead Sponsor
- Sophiris Bio Corp
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- ot Recruiting
- Sex
- Not specified
- Target Recruitment
- 20
1.Men aged =40 years and life expectancy of =10 years.
2.Serum prostate specific antigen (PSA) =15ng/mL.
3.In the planned treatment zone, histologically proven prostate cancer of maximum Gleason Score 7 (3+4 or 4+3)
•In the presence of Gleason sum of 7, the maximum cancer core length must be 10mm or less
•In the presence of Gleason sum of 7 there is no minimum cancer core length involvement
•In the presence of Gleason patterns 3+3 the minimum cancer core length must exceed 3mm.
4.Radiological stage T1-T2 N0 Mx/M0 disease.
5.A visible lesion on mpMRI that is accessible to PRX302 transperineal injection. mpMRI to be obtained at the screening visit or within 3 months prior to dosing.
6.Transperineal prostate biopsy (template mapping and/or targeted) within 12 months prior to dosing, with a clinically significant lesion correlating with an mpMRI visible lesion.
7.Written informed consent by the patient for participation in the study.
8.Patient has an understanding of the English language sufficient to understand written and verbal information about the study and consent process.
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 15
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 5
1.Previous radiation therapy to the pelvis.
2.Androgen suppression or anti-androgen therapy within the 12 months prior to dosing, for prostate cancer.
3.Use of a 5-alpha reductase inhibitor within the 3 months prior to dosing.
4.Evidence of metastatic disease or nodal disease outside the prostate on bone scan or cross-sectional imaging.
5.Presence of Gleason score >7 and/or maximum cancer core length involvement of >3mm outside of the planned treatment zone.
6.A tumour within the prostate not visible on mpMRI.
7.Inability to tolerate a transrectal ultrasound (TRUS).
8.Known allergy to latex or gadolinium (Gd).
9.Prior rectal surgery preventing insertion of the TRUS probe.
10.Previous electroporation, radiofrequency ablation, high-intensity focused ultrasound (HIFU), cryosurgery, thermal or microwave therapy to treat cancer of the prostate.
11.Transurethral resection of the prostate (TURP) for symptomatic lower urinary tract symptoms within the 6 months prior to dosing.
12.Not fit for major surgery as assessed by a Consultant Anaesthetist.
13.Unable to have pelvic MRI scanning (severe claustrophobia, permanent cardiac pacemaker, metallic implant, etc. likely to contribute significant artefact to images).
14.Presence of metal implants/stents in the urethra or any other non-MRI compatible metal objects.
15.Renal impairment with an estimated glomerular filtration rate (GFR) of <35mL/min (unable to tolerate Gd dynamic contrast enhanced MRI).
16.Use of ANY of the following medications:
•Anticoagulants (e.g., Coumadin, heparin) or platelet inhibitors (e.g., aspirin, nonsteroidal anti-inflammatory drugs [NSAIDs], clopidogrel [e.g., Plavix®]) within 5 days prior to dosing or anticipated for use any time within the first 3 days after dosing or per local guidelines.
•Androgen deprivation therapy will not be permitted during study duration unless the development of metastases (rare) occurred during study follow-up. 5-alpha reductase inhibitors will not be permitted during the study until the post-treatment biopsies have been taken.
17.Any condition that may confound the assessment of safety and tolerability, such as current symptomatic prostatitis; acute or chronic or symptomatic genitourinary infection; or urinary retention requiring catheterisation within 12 months prior to dosing or elevated International Normalized Ratio (INR) > 1.5 at the time of dosing.
18.Any acute or chronic medical condition that, in the opinion of the Investigator, increases the risk to the patient or the likelihood that the patient will be unable to complete the 30-week study.
19.Unable or unwilling to comply with the requirements of the protocol.
20.Participation in any investigational study within 30 days prior to dosing.
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method